<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/3/2021 9:05:35 PM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: aaea48a6-d545-431e-83ea-25d0008495c9 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ampe="http://www.ampiopharma.com/20210303" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:EntityCentralIndexKey" id="Tc_CUHqGSiGEUinbJtWAAzv8A_2_1">0001411906</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:AmendmentFlag" id="Tc_lI8KDgiTD0iZF6FcP9yYzA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ampe-20210303.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411906</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-29</xbrli:startDate><xbrli:endDate>2020-12-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_88fad6b2_b87c_48b9_a640_1fda75f41c7f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:DocumentType" id="Narr_VLf1Hrt2A0CFQ3t6z0FS-A"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION&#160;13 OR 15(d)&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_CYn_sYix-Uy8ZqyUvZ364g"><b style="font-weight:bold;">March 3, 2021</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:EntityRegistrantName" id="Narr_etZPQTpJtkSd9bRwFNSIng"><b style="font-weight:bold;">AMPIO PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_79514924_cfb6_493d_a1f5_0086496939a5"></a><a id="Tc_E3rBn3ZAPUCBNnUMTFu2sg_2_0"></a><a id="Tc_uxmsgu6JBkKsji-Kc2CxVQ_2_1"></a><a id="Tc_M9AdLJWmO0-UNHCLMlsPUA_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.04%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_a46BNsyGg0exyG1A9AcTTQ_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.04%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:EntityFileNumber" id="Tc_2cGsh4LSdUeBvrUceYCY7g_1_1"><b style="font-weight:bold;">001-35182</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:EntityTaxIdentificationNumber" id="Tc_IxEPTbG3Pk2kb0np8CckbQ_1_2"><b style="font-weight:bold;">26-0179592</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:33.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(State or other jurisdiction of<br />incorporation)</b></p></td><td style="vertical-align:top;width:33.04%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:33.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">(IRS Employer Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:EntityAddressAddressLine1" id="Narr_aAsC-Dwb9ECErDKnDM6WRw"><b style="font-weight:bold;">373 Inverness Parkway, Suite 200</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:EntityAddressCityOrTown" id="Narr_Jee0dlyp1kWNuqqjwMmJww"><b style="font-weight:bold;">Englewood</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_SlPhk5duLECM2FTi5LJuGg"><b style="font-weight:bold;">Colorado</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:EntityAddressPostalZipCode" id="Narr_tdFus08sNkKXtccT3SeRzw"><b style="font-weight:bold;">80112</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices) (Zip Code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:CityAreaCode" id="Narr_zv_VFJl9kU-fK5NY-PB1kA"><b style="font-weight:bold;">720</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:LocalPhoneNumber" id="Narr_kYxAWdeMlU6982vSM7lvVg"><b style="font-weight:bold;">437-6500</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Not Applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Former name, or former address, if changed since last report)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:5pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_zQzXAdXhs0CGvra1ABzyHA"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_oEI2q6srOk-0-nJuaxxWTg"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_QbVAmZxX1kqog_cxYWedgg"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_BHJMFG44qkePKmS4ZvAgXw"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8d10a49f_7efa_4e2d_926b_73f0a2da03d5"></a><a id="Tc_-sx0NdW_AEOwBbL8YvjEeA_1_0"></a><a id="Tc_oMQZIwWqNUGCYzErE9cvXQ_1_1"></a><a id="Tc_qxD3hQ-XkEO39h_SIl_VUQ_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:37.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:40.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;">Title of each class</p></td><td style="vertical-align:top;width:22.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;">Trading Symbol</p></td><td style="vertical-align:top;width:37.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:Security12bTitle" id="Tc_GImD-SHs0k6pzxbgmEVYag_2_0"><span style="font-size:9pt;">Common Stock, $0.0001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" name="dei:TradingSymbol" id="Tc_D55E2t9fRkeKzVNviiQ8oQ_2_1"><span style="font-size:9pt;">AMPE</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:37.56%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_39OXqi81DEWn5NaK0iltfQ_2_2"><span style="font-size:9pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_12_29_2020_To_12_29_2020_sv2VPfU3E0WzvwmUePygUw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_v7krRuoaREeqAUItT_VnTQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4a5b1e98_84a7_448c_b92b_216ae30aecf4"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.43;text-align:left;">Item 2.02</b></span><b style="font-weight:bold;">Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;">On March 3, 2021, Ampio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing operating and financial highlights for the quarter and year ended December 31, 2020.  </span>A copy of the Company&#8217;s press release is furnished as Exhibit 99.1 on this Current Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;">The information in this Form 8-K is furnished under &#8220;Item 2.02 Results of Operations and Financial Condition&#8221; and Exhibit 99.1, attached hereto, and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of&#160;1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. It may be incorporated by reference in a filing under the Exchange Act or the Securities Act of 1933, as amended, only if such subsequent filing specifically references such disclosure in this Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;9.01</b></p></td><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">(d)    Exhibits.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">99.1</span></span><a style="-sec-extract:exhibit;" href="ampe-20210303xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press release, dated March 3, 2021.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">104</span></span>The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d7c89071_ec46_4543_ad05_2b17fb91b6ac"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9kMHG5YVt48867FT4rw"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:42.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AMPIO PHARMACEUTICALS, INC. </b></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;March 3, 2021</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.15%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Daniel G. Stokely</p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42.15%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Daniel G. Stokely</p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:42.15%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Financial Officer and Secretary</p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Cambria Math';visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "ampe-20210303x8k.htm", "description": "8-K", "secsgml_size_bytes": 33175}]
{"company-data": {"conformed-name": "Ampio Pharmaceuticals, Inc.", "cik": "0001411906", "assigned-sic": "2834", "irs-number": "260179592", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35182", "film-number": "21708918"}, "business-address": {"street1": "373 INVERNESS PARKWAY", "street2": "SUITE 200", "city": "ENGLEWOOD", "state": "CO", "zip": "80112", "phone": "720-437-6500"}, "mail-address": {"street1": "373 INVERNESS PARKWAY", "street2": "SUITE 200", "city": "ENGLEWOOD", "state": "CO", "zip": "80112"}, "former-company": {"former-conformed-name": "Chay Enterprises, Inc.", "date-changed": "20070910"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 3, 2021
AMPIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
​
​
​
​
Delaware
001-35182
26-0179592
(State or other jurisdiction of
incorporation)
(Commission File Number)
(IRS Employer Identification No.)
​
373 Inverness Parkway, Suite 200
Englewood
,
Colorado
80112
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (
720
)
437-6500
​
Not Applicable
(Former name, or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
​
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value
AMPE
NYSE American
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
Item 2.02
Results of Operations and Financial Condition.
On March 3, 2021, Ampio Pharmaceuticals, Inc. (the "Company") issued a press release announcing operating and financial highlights for the quarter and year ended December 31, 2020.
A copy of the Company's press release is furnished as Exhibit 99.1 on this Current Report on Form 8-K.
The information in this Form 8-K is furnished under "Item 2.02 Results of Operations and Financial Condition" and Exhibit 99.1, attached hereto, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may be incorporated by reference in a filing under the Exchange Act or the Securities Act of 1933, as amended, only if such subsequent filing specifically references such disclosure in this Form 8-K.
​
Item 9.01
Financial Statements and Exhibits.
​
(d)    Exhibits.
99.1
Press release, dated March 3, 2021.
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
​
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
AMPIO PHARMACEUTICALS, INC.
Date:  March 3, 2021
By:
/s/ Daniel G. Stokely
Name: Daniel G. Stokely
Title: Chief Financial Officer and Secretary
​
​
​
​
​